Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15417325 | 0.81 | RAB9A (0.42) | NPC1RAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL24959995 | 0.81 | NPC1 (0.42) | NPC1RAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL24960094 | 0.80 | NPC1 (0.48) | NPC1RAB9ACYP2C9HPGDTSHR | |
| SCHEMBL24956359 | 0.78 | NPC1 (0.52) | NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL24956358 | 0.78 | NPC1 (0.56) | NPC1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL24960091 | 0.78 | HPGDS (0.42) | NPC1RAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL24960109 | 0.77 | TGFBR1 (0.46) | NPC1RAB9ATSHRBRD4SMN1; SMN2 | |
| SCHEMBL17806604 | 0.76 | BRD4 (0.46) | MAPTTLR8TLR7GPR6BRD4 | |
| SCHEMBL21989562 | 0.75 | KDM4E (0.42) | NPC1RAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL31224325 | 0.75 | NPC1 (0.42) | NPC1RAB9AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | NPC1 1188/4885RAB9A 478/4885KDM4E 2322/4885 |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | NPC1 2940/4885RAB9A 3330/4885KDM4E 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.